Research Overview
Recent research on chamomile in the provided abstracts focuses primarily on two clinical domains: metabolic outcomes related to diabetes (glycemic control) and gynecologic pain symptoms (endometriosis-associated pelvic pain, dyspareunia, and dysmenorrhea). The glycemic-control literature summarized here includes a systematic review and meta-analysis spanning both human randomized controlled trials (RCTs) and animal studies, indicating that this area has been studied across multiple model systems, though with a limited number of human trials. The endometriosis literature includes a controlled randomized clinical trial comparing chamomile to flaxseed and placebo over 8 weeks, reflecting targeted investigation of chamomile as a symptom-modifying intervention for pain-related outcomes.
The strongest evidence in these abstracts supports modest improvements in glycemic markers and reductions in pain symptoms. In the meta-analysis of RCTs, chamomile consumption was associated with statistically significant reductions in fasting blood glucose and HbA1c, with low heterogeneity for fasting glucose and moderate heterogeneity for HbA1c, suggesting a potentially consistent effect on fasting glucose across the included trials. Animal studies also showed substantial glucose-lowering effects and suggested a dose–response relationship, although heterogeneity was high in dose–response analyses. In endometriosis, the randomized trial reported significantly lower pelvic pain, dyspareunia, and dysmenorrhea scores in the chamomile group compared with placebo at 1- and 2-month follow-ups, supporting a potential symptomatic benefit for pain outcomes over the studied timeframe.
Key gaps include the need for additional well-powered, rigorously designed human RCTs to confirm efficacy, clarify optimal dosing and formulation (e.g., tea vs standardized extract vs capsules), and establish durability of effects and safety with longer-term use. For glycemic outcomes, more trials are needed to determine clinical relevance (absolute changes in glucose/HbA1c), effects in diverse patient populations, and interactions with standard glucose-lowering medications. For endometriosis-related pain, replication across settings and comparison against established therapies, along with mechanistic studies (e.g., anti-inflammatory or antispasmodic pathways) and standardized outcome reporting, would strengthen confidence in the findings and help define where chamomile fits in evidence-based care.
1. What conditions has Chamomile been studied for?
Glycemic control in diabetes / hyperglycemia: Studied in humans (randomized controlled trials) and in animal models for effects on fasting blood glucose and HbA1c.
Endometriosis-related pain symptoms: Studied in a randomized clinical trial for pelvic pain, dyspareunia (pain with intercourse), and dysmenorrhea (painful menstruation).
2. Does it work in treating those conditions? Summarize the evidence.
-
Glycemic control (humans): A systematic review/meta-analysis including 4 clinical trials found chamomile consumption was associated with improvements in:
Fasting blood glucose: SMD -0.65 (95% CI: -1.00 to -0.29), P<0.001; heterogeneity I2=0% (consistent across included RCTs).
HbA1c: SMD -0.90 (95% CI: -1.39 to -0.40), P<0.001; I2=45.4% (moderate heterogeneity).
Interpretation: Evidence suggests benefit, but the number of human trials is small; the authors explicitly note that more RCTs are needed to confirm findings.
-
Glycemic control (animals): The same meta-analysis included 8 animal studies and found a large reduction in blood glucose (SMD -4.37, 95% CI: -5.76 to -2.98; P<0.001; I2=61.2%). A dose-response analysis reported that each 100 mg/day increase in chamomile extract was associated with a further decrease in glucose (MD -54.35; 95% CI: -79.77 to -28.93; P<0.001), though heterogeneity was very high (I2=94.8%).
Interpretation: Animal data support a glucose-lowering effect, but high heterogeneity and translation limits from animals to humans reduce certainty.
-
Endometriosis-related pain (humans): A controlled randomized clinical trial in 102 endometriosis patients compared chamomile vs flaxseed vs placebo. Participants took 1000 mg capsules three times daily for 8 weeks. Pain outcomes (VAS) were assessed at baseline and follow-ups. Compared with placebo, the chamomile group showed significantly lower:
Pelvic pain at 1 and 2 months (reported as significantly lower vs placebo; P<0.001).
Dyspareunia at 1 and 2 months (significantly lower vs placebo; P<0.001).
Dysmenorrhea at 1 and 2 months (significantly lower vs placebo; P<0.001).
Interpretation: This trial supports a pain-reducing effect for endometriosis-associated symptoms over 8 weeks, but it is a single-center study and the abstract does not provide effect sizes, adverse events, or longer-term outcomes.
3. What health benefits does it have?
-
Improved glycemic markers (based on the meta-analysis of RCTs):
Lower fasting blood glucose.
Lower HbA1c (a longer-term marker of glycemic control).
-
Reduction of endometriosis-related pain symptoms (based on the randomized clinical trial):
Reduced pelvic pain.
Reduced dyspareunia.
Reduced dysmenorrhea.
Note: These benefits are supported by the provided abstracts; they do not establish effectiveness for other commonly claimed uses of chamomile (e.g., sleep/anxiety) because those outcomes were not included in the supplied evidence.
4. Does it have any downsides or side effects?
-
Not reported in the provided abstracts: Neither abstract includes adverse event rates, tolerability details, or discontinuation due to side effects.
-
Practical safety considerations (limitations of the evidence here):
Because chamomile may lower glucose in some settings, a plausible concern (especially when combined with glucose-lowering medications, as noted in the diabetes abstract’s background) is additive glucose-lowering. However, the abstracts do not report hypoglycemia events or medication-interaction outcomes.
The endometriosis trial used a relatively high dose regimen (3000 mg/day for 8 weeks), but the abstract does not describe side effects, so tolerability at this dose cannot be assessed from the provided information.
If you want, I can summarize known chamomile adverse effects and interaction risks from broader clinical references, but they are not contained in these abstracts.
5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?
No pharmacogenomic findings are provided: The abstracts do not mention genetic variants, genotype-stratified responses, or metabolism pathways tied to specific genes.
Evidence gap: Based on the supplied research summaries, there is insufficient information to say chamomile is beneficial or harmful for any specific genetic variation.
References
-
The effect of chamomile consumption on glycemic markers in humans and animals: a systematic review and meta-analysis
Camellia Akhgarjand, Jalal Moludi, Sara Ebrahimi-Mousavi, Amir Bagheri, Narges Ghorbani Bavani (2023) -
The Effects of Chamomile and Flaxseed on Pelvic Pain, Dyspareunia, and Dysmenorrhea in Endometriosis: A Controlled Randomized Clinical Trial
Zohre Khalajinia, Fatemeh Mohanazadeh Falahieh, Mohammad Aghaali (2024)
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!